


Fig. 3. NK cells are primed by CD11b⁺Gr1⁺ cells isolated from poly I:C-injected tumor-bearing mice. **a-c** CD11b⁺Gr1⁺ cells were isolated from spleens or tumors of B16 (**a**), 3LL (**b, c**) tumor-bearing mice pretreated with 200 μg poly I:C or PBS for 4 h and cultured with NK cells from naïve WT mice. After 24 h, CD69 expression on NK cells (**a-c**, left panels) and IFN-γ concentration in conditioned medium (**a-c**, right panels) were determined. CD69 expression of NK1.1⁺CD3ε⁻ cells is indicated (**a-c**). N.T. = Not tested. **d** Cytotoxic activity of NK cells cocultured with or without CD11b⁺Gr1⁺ cells isolated from poly I:C- or PBS-treated tumor-bearing mice was determined by standard ⁵¹Cr release assay (n = 3). Triangle: NK cells not cultured with CD11b⁺Gr1⁺ cells. Data shown are representative of at least 3 independent experiments. ** p < 0.01.







Fig. 4. Type-I IFNs from CD11b⁺Gr1⁺ cells and IFNAR in NK cells are indispensable for NK cell activation. **a** CD11b⁺Gr1⁺ cells were isolated from spleens of B16 tumor-bearing mice treated with 200 μ g poly I:C or PBS for 4 h and cultured with NK cells from naïve WT mice in the presence or absence of 10 μ g/ml anti-IFNAR1 antibody (Ab). After 24 h, CD69 expression on NK cells (left panels) and IFN- γ concentration in conditioned medium (right panel) was determined ($n = 3$). **b** CD11b⁺Gr1⁺ cells isolated as described in **a** were cultured for 24 h with NK cells from naïve WT mice or

IFNAR1^{-/-} mice, and CD69 expression (left panels) and IFN- γ production were measured ($n = 3$) (right panel). **c** Recombinant IFN- α was added to cultures of naïve NK cells with or without CD11b⁺Gr1⁺ cells from nontreated tumor-bearing mice. After incubation for 24 h, CD69 expression on NK cells (left panels) and IFN- γ concentration in conditioned medium (right panel) were determined ($n = 3$). CD69 expression of NK1.1⁺CD3 ϵ ⁻ cells is indicated (**a-c**). Data shown are representative of two independent experiments. ** $p < 0.01$.

Fig. 5. Retardation of B16 tumor growth by poly I:C treatment in mouse models. **a** Both TICAM-1 and MAVS signals are involved in B16 tumor growth retardation after poly I:C therapy. B16 cells (6×10^5) were implanted s.c. into WT, TICAM-1^{-/-}, MAVS^{-/-} and TICAM-1 and MAVS double-knockout mice. Tumor-bearing mice were treated with 200 μ g poly I:C or PBS on days 10 and 14 (arrows) ($n = 3-5$ per group). Data are average \pm SEM. **b** In vivo poly I:C-activated CD11b⁺Gr1⁺ cells inhibit B16 tumor growth. B16 cells (6×10^5) were mixed with or without CD11b⁺Gr1⁺ cells (1×10^6) from spleens of B16 tumor-bearing mice treated with 200 μ g poly I:C or PBS for 4 h. Cell mixtures were implanted s.c. into WT mice on day 0 ($n = 4$ per group). Data are average \pm SEM and are representative of 2 independent experiments. ** $p < 0.01$, * $p < 0.05$.




together with the results in figure 4, suggest that two modes of NK priming occur simultaneously in CD11b⁺Gr1⁺ cells: one mode is through type-I IFN production and the other is via cell-cell contact.

MAVS and IFNAR Are Required to Activate MDSCs with in vivo Poly I:C Treatment

Poly I:C induces growth retardation of B16 tumors implanted in WT mice [4–6, 36]. To determine the signaling pathway that is essential for the retardation of B16 tumor

growth in vivo, we implanted B16 melanoma cells s.c. into TICAM-1^{-/-} and MAVS^{-/-} mice. B16 tumor growth was monitored after poly I:C injection. Marked tumor growth retardation was observed in poly I:C-treated mice (fig. 5a). The poly I:C antitumor effect was only partly abrogated in either TICAM-1^{-/-} or MAVS^{-/-} mice and was completely abolished in TICAM-1^{-/-}/MAVS^{-/-} mice (fig. 5a). Therefore, both TICAM-1 and MAVS signals are involved in the antitumor activity of poly I:C, consistent with earlier reports [4, 5, 33].

Fig. 6. MAVS and type-I IFN signaling pathways are critical for CD11b⁺Gr1⁺ cell activation in vivo. **a** B16 cells (6×10^5) were implanted into WT, TICAM-1^{-/-}, MAVS^{-/-} or IFNAR1^{-/-} mice. Tumor-bearing mice were treated with 200 μ g poly I:C or PBS for 4 h and CD11b⁺Gr1⁺ cells were isolated from spleens, and allowed to stand for 24 h. IFN- α concentration in conditioned medium was determined (n = 3). **b**, **c** CD11b⁺Gr1⁺ cells were isolated from KO mouse lines as described in **a**, and were cultured with naïve WT NK cells for 24 h. CD69 expression on NK cells (**b**) and IFN- γ concentration in conditioned medium (**c**) were determined (n = 3). Data shown are representative of 3 independent experiments. ** p < 0.01.



Next, we determined the mechanisms involved in the in vivo activation of CD11b⁺Gr1⁺ cells by poly I:C. To investigate the signaling pathway that was important for poly I:C-induced activation of CD11b⁺Gr1⁺ cells in vivo, we challenged TICAM-1^{-/-} and MAVS^{-/-} mice with B16 melanoma cells. After tumor formation, poly I:C was injected i.p. into the mice and CD11b⁺Gr1⁺ cells were isolated from the spleen and were cocultured with naïve WT NK cells. CD11b⁺Gr1⁺ cells from tumor-bearing TICAM-1^{-/-} mice produced IFN- α at levels comparable to cells from WT mice (fig. 6a). In parallel, CD69 expression on NK cells and IFN- γ production was observed in conditioned medium

from mixed cultures of TICAM-1^{-/-} CD11b⁺Gr1⁺ cells and naïve WT NK cells. The results suggest that in vivo TICAM-1 signaling is not mandatory for CD11b⁺Gr1⁺ cell activation to induce NK cell priming (fig. 6a-c). CD11b⁺Gr1⁺ cells from tumor-bearing MAVS^{-/-} mice treated with poly I:C did not produce IFN- α or induce CD69 expression and IFN- γ production in NK cells (fig. 6a-c). Similar results were obtained with CD11b⁺Gr1⁺ cells from B16 tumor-bearing IFNAR1^{-/-} mice (fig. 6a-c). These results suggest that MAVS as well as type-I IFN signaling is crucial for poly I:C-dependent NK cell priming in CD11b⁺Gr1⁺ cells of tumor-bearing mice.

The MAVS pathway is conserved in most cell types in mice. We examined whether NK cell priming induced by poly I:C (i.e. MAVS signal)-activated CD11b⁺Gr1⁺ cells was involved in retardation of B16 tumor growth. NK-sensitive B16 tumor cells were mixed with CD11b⁺Gr1⁺ cells isolated from poly I:C (or control PBS)-injected tumor-bearing mice, and inoculated s.c. into WT mice (fig. 5b). Significant B16 growth retardation was detected only in those tumors containing poly I:C-treated CD11b⁺Gr1⁺ cells (fig. 5b). The B16 tumors with intact CD11b⁺Gr1⁺ cells showed higher growth rates than B16 tumor cells only, which might reflect the previously-reported tumor-supporting activity of MDSCs [37]. Thus, MDSC-like CD11b⁺Gr1⁺ cells can be converted to cells with an NK-priming activity that induces growth retardation of NK-sensitive tumors in mice. NK-priming would be a condition prior to full activation of antitumor NK cells.

Discussion

We demonstrated that *in vivo* poly I:C treatment led to CD11b⁺Gr1⁺ MDSC maturation and cytokine production in tumor-bearing mice. Poly I:C treatment rendered tumor and spleen MDSCs competent for DX5⁺ NK cell priming as measured by CD69 expression and IFN- γ production. Poly I:C-dependent NK priming raises through the MAVS pathway (fig. 6). Among a number of proteins that were upregulated after poly I:C treatment, type-I IFN produced by activated MDSCs was critical for NK cell priming since it activated the IFNAR pathway in NK cells. However, NK cells barely exerted direct cytotoxic activity to B16 cells in response to poly I:C-matured MDSCs. This NK activation profile resembles that of IFN- γ -producing innate lymphoid cells. Some populations of these innate lymphocytes produce IFN- γ but exhibit little cytotoxic activity [38], similar to the NK cells affected by MDSC. These findings would allow us to speculate that the production of IFN- γ without cytotoxic activity is an activation state of NK cells or innate lymphocytes where MDSCs contribute.

In tumor-bearing hosts, poly I:C treatment resulted in tumor regression. Poly I:C induces direct killing of 3LL tumor cells by M2-M1 conversion of tumor-associated macrophages [7]. The TICAM-1 signal facilitates tumor-associated macrophage conversion as well as cross-presentation by DCs leading to antigen-specific CTL induction, which is also evoked by poly I:C [8]. The action of CD11b⁺Gr1⁺ MDSCs on implant B16 tumor was tumor-

supporting when MDSCs were embedded into the tumor (fig. 5b). However, once MDSCs were pretreated with poly I:C and mixed with B16 cells, tumor growth was prohibited (fig. 5b). The result suggests that MDSC has plasticity to change the function from tumor-supporting to tumor-suppressing even *in vivo*. Here, we highlight the first evidence of MDSCs to evoke NK cell priming, which ultimately associates with retardation of tumor growth.

Although the exact mechanism of tumor regression by MDSC-NK activation remains to be elucidated, we speculate that IFN- γ produced by the primed NK cells could evoke antitumor activity. One possibility is that IFN- γ directly inhibits the growth of a certain tumor line including B16 melanoma by inducing cell cycle arrest. IFN- γ has a synergistic effect on type-I IFNs, arresting cell cycle to cell death in some tumor cell lines independent of p53 [39]. IFN- γ also induces angiostasis, which prevents rapid tumor progression [19], and inhibits metastasis and proliferation of B16 melanoma [17, 20]. In fact, we observed that IFN- γ directly inhibits proliferation of B16 cells *in vitro*, suggesting that NK cell-derived IFN- γ might inhibit B16 tumor growth during poly I:C treatment (online suppl. fig. 3).

Retardation of B16 growth was partially abrogated in TICAM-1^{-/-} or MAVS^{-/-} mice and completely abrogated in TICAM-1^{-/-}, MAVS^{-/-} double KO mice (fig. 5a), the two pathways contributing to *in vivo* poly I:C-derived tumor suppression. In addition, MDSC activation is completely abrogated in IFNAR1^{-/-} mice and IFNAR in NK cells is involved in efficient IFN- γ production induced by activated MDSCs. Type-I IFN receptor signaling is crucial for growth retardation of B16 tumor in poly I:C therapy. Therefore, a variety of situations result in NK activation/priming in the therapeutic use of poly I:C in tumor-bearing mice, although IFNAR is the common factor.

Miyake et al. [5], reported that MAVS is responsible for NK cell-dependent tumor regression using MAVS^{-/-} mice with poly I:C stimulation; however, the cell types for the poly I:C response and the mechanism of induction of NK-sensitive tumor regression remain undefined. NK-activating ligands on the DC surface as well as soluble factors induced by IRF-3 and IFNAR stimulation are crucial for DC-mediated NK cell activation [15, 32]. In addition, MDSC is a cell type that specifically drives NK priming through the MAVS pathway (fig. 6). MAVS-dependent IRF-3 activation occurs through stromal cells other than DCs, and these cells including MDSCs participate in NK-sensitive tumor regression. The result of this MDSC function is in contrast to that of DCs where the TLR3/TICAM-1 pathway preferentially promotes NK cell acti-

vation [4]. Specific depletion of MDSCs in preformed tumors, if possible, would enable us to confirm the functional importance of MAVS in tumor regression reported by Miyake et al. [5], who postulated that stromal cells were a source of the cell type that induces MAVS-mediated NK priming. However, the function of poly I:C via the MDSC-NK cell pathway is only a part of the total antitumor activity of poly I:C, which would be difficult to detect by tumor-size reduction. MDSCs are expanded in a late phase of implant tumor, where poly I:C may act on MDSCs and exert antitumor activity via poly I:C-stimulated MDSCs.

A recent report suggested that type-I IFNs act on accessory cells such as DCs, leading to the production of IL-15, IL-12, IL-18 and NKG2D ligands such as RAE-1. IFN- α acted on NK cells and slightly induced IFN- γ production, which was augmented in the presence of MDSCs. Cell-cell interaction between MDSCs and NK cells appears to be required for robust IFN- γ production. Induction of NK-activating ligands in association with natural NK cytotoxicity is involved in cell-cell contact-mediated NK cell activation. We found mRNA for downstream genes of IRF-3, especially IL-15, IL-18, INAM and RAE-1 elevated in MDSCs after treatment with poly I:C. However, IL-15 and RAE-1 appear not to participate in IFN- γ production by NK cells with MDSCs because neutralizing antibodies to IL-15, RAE-1 or NKG2D did not inhibit IFN- γ production by NK cells. Therefore, other molecules should be involved in NK cell activation by MDSCs. In fact, INAM or other molecules expressed on the MDSC surface sustain NK cell activation following poly I:C treat-

ment (fig. 2; data not shown) as in bone marrow-derived cells [32].

MDSCs that have expanded in tumor-bearing hosts strongly suppress antitumor immune responses [22, 23]. Reduction of MDSC population or function is achieved by treatment with reagents that are related to improvement in tumor-specific immunity [40]. Furthermore, maturation of MDSCs can be accomplished through IFN- α production by plasmacytoid DCs or direct TLR9 stimulation, which contributes to tumor regression [30, 31]. Direct administration of IFN- α , i.e. IFN therapy, however, has not been successful as a universal therapy in cancer patients. Serious side effects are associated with high therapeutic doses of type-I IFN as well as poly I:C. Development of less toxic reagents with sufficient IRF-3/7 activation would be important for anti-MDSC cancer therapy.


Acknowledgements

We thank Drs. H. Takaki, J. Kasamatsu, K. Funami, M. Tatamatsu and M. Azuma in our laboratory for their fruitful discussions. This work was supported in part by Grants-in-Aids from the Ministry of Education, Science and Culture (specified project for advanced research) and the Ministry of Health, Labor and Welfare of Japan as well as by the Akiyama Life Science Foundation (H.S.), the Takeda Science Foundation (H.S.), the Yasuda Cancer Foundation (T.S.) and the Ono Foundation (T.S.). Financial support by a MEXT Grant-in-Project 'the Carcinogenic Spiral', 'the National Cancer Center Research and Development Fund (23-A-44)', and the Japan Initiative for Global Research Network on Infectious Diseases is gratefully acknowledged.

References

- Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al: Trial watch: experimental Toll-like receptor agonists for cancer therapy. *Oncoimmunol* 2012;1:699–716.
- Desmet CJ, Ishii KJ: Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. *Nat Rev Immunol* 2012;12:479–491.
- Seya T, Shime H, Ebihara T, Oshiumi H, Matsumoto M: Pattern recognition receptors of innate immunity and their application to tumor immunotherapy. *Cancer Sci* 2010;101:313–320.
- Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, et al: Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. *Proc Natl Acad Sci USA* 2007;104:252–257.
- Miyake T, Kumagai Y, Kato H, Guo Z, Matsushita K, Satoh T, et al: Poly I:C-induced activation of NK cells by CD8 α + dendritic cells via the IPS-1 and TRIF-dependent pathways. *J Immunol* 2009;183:2522–2528.
- Salem ML, El-Naggar SA, Kadima A, Gillanders WE, Cole DJ: The adjuvant effects of the Toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. *Vaccine* 2006;24:5119–5132.
- Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, et al: Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. *Proc Natl Acad Sci USA* 2012;109:2066–2071.
- Azuma M, Ebihara T, Oshiumi H, Matsumoto M, Seya T: Cross-priming for antitumor CTL induced by soluble Ag + poly I:C depends on the TICAM-1 pathway in mouse CD11c+/CD8 α + dendritic cells. *Oncoimmunol* 2012;1:581–592.
- Gauzzi MC, Del Corno M, Gessani S: Dissecting TLR3 signalling in dendritic cells. *Immunobiology* 2010;215:713–723.
- Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T: TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon- β induction. *Nat Immunol* 2003;4:161–167.
- Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al: Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. *Science* 2003;301:640–643.
- Seth RB, Sun L, Ea C-K, Chen ZJ: Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF- κ B and IRF3. *Cell* 2005;122:669–682.

- 13 Honda K, Takaoka A, Taniguchi T: Type I interferon gene induction by the interferon regulatory factor family of transcription factors. *Immunity* 2006;25:349–360.
- 14 Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, et al: Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. *Nat Immunol* 2004;5:1061–1068.
- 15 Seya T, Kasamatsu J, Azuma M, Shime H, Matsumoto M: Natural killer cell activation secondary to innate pattern sensing. *J Innate Immun* 2011;3:264–273.
- 16 Zama L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, et al: NK cells and cancer. *J Immunol* 2007;178:4011–4016.
- 17 Takeda K, Nakayama M, Sakaki M, Hayakawa Y, Imawari M, Ogasawara K, et al: IFN- γ production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. *J Leukoc Biol* 2011;90:777–785.
- 18 Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S: Functions of natural killer cells. *Nat Immunol* 2008;9:503–510.
- 19 Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, et al: IFN- γ -mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α -galactosylceramide. *Blood* 2002;100:1728–1733.
- 20 Kakuta S, Tagawa Y-I, Shibata S, Nanno M, Iwakura Y: Inhibition of B16 melanoma experimental metastasis by interferon-gamma through direct inhibition of cell proliferation and activation of antitumor host mechanisms. *Immunology* 2002;105:92–100.
- 21 Newman K, Riley E: Whatever turns you on: accessory-cell-dependent activation of NK cells by pathogens. *Nat Rev Immunol* 2007;7:279–291.
- 22 Gabrilovich DI, Ostrand-Rosenberg S, Bronte V: Coordinated regulation of myeloid cells by tumours. *Nat Rev Immunol* 2012;12:253–268.
- 23 Ostrand-Rosenberg S, Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. *J Immunol* 2009;182:4499–4506.
- 24 Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C, et al: Origins of tumor-associated macrophages and neutrophils. *Proc Natl Acad Sci USA* 2012;109:2491–2496.
- 25 Ostrand-Rosenberg S: Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. *Cancer Immunol Immunother* 2010;59:1593–1600.
- 26 Li H, Han Y, Guo Q, Zhang M, Cao X: Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF- β 1. *J Immunol* 2009;182:240–249.
- 27 Hoechst B, Voigtlaender T, Ormandy L, Gamrekeshvili J, Zhao F, Wedemeyer H, et al: Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. *Hepatology* 2009;50:799–807.
- 28 Liu C, Yu S, Kappes J, Wang J, Grizzle WE, Zinn KR, et al: Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. *Blood* 2007;109:4336–4342.
- 29 Nausch N, Galani IE, Schlecker E, Cerwenka A: Mononuclear myeloid-derived ‘suppressor’ cells express RAE-1 and activate natural killer cells. *Blood* 2008;112:4080–4089.
- 30 Zoglmeier C, Bauer H, Nörenberg D, Wedekind G, Bittner P, Sandholzer N, et al: CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. *Clin Cancer Res* 2011;17:1765–1775.
- 31 Shirota Y, Shirota H, Klinman DM: Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. *J Immunol* 2012;188:1592–1599.
- 32 Ebihara T, Azuma M, Oshiumi H, Kasamatsu J, Iwabuchi K, Matsumoto K, et al: Identification of a poly(I:C)-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation. *J Exp Med* 2010;207:2675–2687.
- 33 McCartney S, Vermi W, Gilfillan S, Cella M, Murphy TL, Schreiber RD, et al: Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. *J Exp Med* 2009;206:2967–2976.
- 34 Takeda K, Oshima H, Hayakawa Y, Akiba H, Atsuta M, Kobata T, et al: CD27-mediated activation of murine NK cells. *J Immunol* 2000;164:1741–1745.
- 35 Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, et al: DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. *J Immunol* 2010;184:902–911.
- 36 Navabi H, Jasani B, Reece A, Clayton A, Tabi Z, Donninger C, et al: A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. *Vaccine* 2009;27:107–115.
- 37 Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. *Nat Biotechnol* 2007;25:911–920.
- 38 Spits H, Artis D, Colonna M, Dieffenbach A, Di Santo JP, Eberl G, et al: Innate lymphoid cells – a proposal for uniform nomenclature. *Nat Rev Immunol* 2013;13:145–149.
- 39 Arany I, Fleischmann CM, Tyring SK, Fleischmann WR: Interferon regulates expression of mda-6/WAF1/CIP1 and cyclin-dependent kinases independently from p53 in B16 murine melanoma cells. *Biochem Biophys Res Commun* 1997;233:678–680.
- 40 Ugel S, Delpozzo F, Desantis G, Papalini F, Simonato F, Sonda N, et al: Therapeutic targeting of myeloid-derived suppressor cells. *Curr Opin Pharmacol* 2009;9:470–481.



MAVS-dependent IRF3/7 bypass of interferon β -induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells

Hiromi Takaki^a, Kenya Honda^b, Koji Atarashi^b, Fukiko Kobayashi^a, Takashi Ebihara^{a,1}, Hiroyuki Oshiumi^a, Misako Matsumoto^a, Masashi Shingai^{a,2,*}, Tsukasa Seya^{a,*}

^a Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo 060-8638, Japan

^b Laboratory for Gut Homeostasis, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan

ARTICLE INFO

Article history:

Received 7 June 2013

Received in revised form 7 August 2013

Accepted 15 August 2013

Available online 4 October 2013

Keywords:

Innate immunity

Dendritic cells

Type I interferon

Mitochondrial antiviral signaling protein

(MAVS)

Measles virus

ABSTRACT

Measles virus (MV) infects CD150Tg/*Irfnar* (IFN alpha receptor)^{-/-} mice but not CD150 (a human MV receptor)-transgenic (Tg) mice. We have shown that bone marrow-derived dendritic cells (BMDCs) from CD150Tg/*Irfnar*^{-/-} mice are permissive to MV in contrast to those from simple CD150Tg mice, which reveals a crucial role of type I interferon (IFN) in natural tropism against MV. Yet, the mechanism whereby BMDCs produce initial type I IFN has not been elucidated in MV infection. RNA virus infection usually allows cells to generate double-stranded RNA and induce activation of IFN regulatory factor (IRF) 3/7 transcription factors, leading to the production of type I IFN through the retinoic acid-inducible gene I (RIG-I)/melanoma differentiation-associated gene 5 (MDA5)-mitochondrial antiviral signaling protein (MAVS) pathway. In mouse experimental BMDCs models, we found CD150Tg/*Mavs*^{-/-} BMDCs, but not CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs, permissive to MV. IFN- α/β were not induced in MV-infected CD150Tg/*Mavs*^{-/-} BMDCs, while IFN- β was subtly induced in CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs. *In vivo* systemic infection was therefore established by transfer of MV-infected CD150Tg/*Mavs*^{-/-} BMDCs to CD150Tg/*Irfnar*^{-/-} mice. These data indicate that MAVS-dependent, IRF3/7-independent IFN- β induction triggers the activation of the IFNAR pathway so as to restrict the spread of MV by infected BMDCs. Hence, MAVS participates in the initial induction of type I IFN in BMDCs and IFNAR protects against MV spreading. We also showed the importance of IL-10-producing CD4⁺ T cells induced by MV-infected BMDCs *in vitro*, which may account for immune modulation due to the functional aberration of DCs.

© 2013 Elsevier Ltd. All rights reserved.

1. Introduction

Recognition of viral RNA in infected cells results in activation of IRF and induction of type I IFN, which initiates potent antiviral responses (Honda et al., 2006; Rathinam and Fitzgerald, 2011).

Abbreviations: BM, bone marrow; MAVS, mitochondrial antiviral signaling protein; MDA5, melanoma differentiation associated gene 5; MV, measles virus; RIG-I, retinoic acid inducible gene-I; TICAM1, Toll/IL-1 receptor homology domain-containing adaptor molecule 1; WT, wild-type.

* Corresponding author at: Department of Microbiology and Immunology, Hokkaido University, Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan. Tel.: +81 11 706 7866; fax: +81 11 706 7866.

E-mail address: seya-tu@pop.med.hokudai.ac.jp (T. Seya).

¹ Present address: Howard Hughes Medical Institute, Rheumatology Division, Department of Medicine, Campus Box 8045, Washington University Medical Center, 660 South Euclid Avenue, St Louis, MO 63110-1093, USA.

² Present address: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

RIG-I and MDA5 sense cytoplasmic viral RNA to activate IRF3/7 through the adaptor MAVS, while TLR3 recognizes extracellular RNA to signal IRF3/7 through the adaptor TICAM-1 (Kawai and Akira, 2006; Matsumoto et al., 2011). Each virus species has its own strategy to circumvent IFN induction, thereby successfully replicating in host cells.

MV is a negative-strand RNA virus, that infects human cells and rapidly induces a Th1 response in children which is characterized by high levels of IFN- γ and IL-2 in the early phase (Griffin et al., 1990). Paradoxically, MV infection is also accompanied by a severe suppression of the immune response that may last for months and this increases the vulnerability to secondary life-threatening infections (Schneider-Schaulies et al., 1995; Moss et al., 2004). Although consensus conclusions are limited in this issue, host dendritic cells (DCs) and acute type I IFN/IL-10 responses are critically implicated in a MV-mediated immune modulation.

It has been reported that V protein of MV wild-type strains blocks IFN-inducing signaling, thereby most wild-type strains can replicate in human cells without interfering with type I IFN

(Takeuchi et al., 2003; Shingai et al., 2007; Ikegame et al., 2010). Several laboratory-adapted strains of MV which produce defective interfering (DI) RNA (Shingai et al., 2007), and a rescued strain called Edmonston tag (Radecke et al., 1995) that harbors C272R-mutated V protein (Ohno et al., 2004), induces type I IFN and explains the mechanism of IFN induction by this MV clone (Takaki et al., 2011). Cytoplasmic RNA sensors, RIG-I and MDA5, are involved in MV RNA recognition and following type I IFN induction (Ikegame et al., 2010), that causes IFNAR-mediated amplification (Takeuchi et al., 2003). RIG-I and MDA5 deliver signals through mitochondrial antiviral signaling protein (MAVS, also called IPS-1/Cardif/VISA) (Yoneyama et al., 2008). Minimal participation of TLRs in MV replication has been reported in human cells including macrophages and dendritic cells (Murabayashi et al., 2002; Tanabe et al., 2003).

The dsRNA-sensing system is believed to be essentially the same in the human and mouse, except that the type I IFN basal level is relatively high in the intact mouse (Shingai et al., 2005). We have made mouse models for analysis of immune aberration induced by various virus infections (Matsumoto et al., 2011). Human CD150 is a main entry receptor for MV, and expressed on DCs, macrophages, T and B cells. (Tatsuo et al., 2000). *Ifnar*^{-/-} mice with transgenic human CD150 (CD150Tg/*Ifnar*^{-/-}) have been used as a MV infection model mouse (Welstead et al., 2005; Shingai et al., 2005; Sellin et al., 2009; Koga et al., 2010) and shown that bone marrow-derived (BM)DCs are highly susceptible to MV (Shingai et al., 2005) as in human monocyte-derived or CD34⁺ progenitor-derived DCs (Fugier-Vivier et al., 1997; Grosjean et al., 1997). Actually, transfer of MV-infected BMDCs to CD150Tg/*Ifnar*^{-/-} mice facilitates establishing systemic MV infection in mice (Shingai et al., 2005).

Here, we generated CD150Tg/*Mavs*^{-/-}, CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-}, and CD150Tg/*Ticam1*^{-/-} mouse sublines and compared the MV-permissiveness of their BMDCs to those of BMDCs from CD150Tg/*Ifnar*^{-/-} mice by *in vitro* MV infection and *in vivo* BMDC-transfer analyses. We found that the IFN response initially elicited by MV was abolished in CD150Tg/*Mavs*^{-/-} BMDCs, but not CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs, and therefore CD150Tg/*Mavs*^{-/-} BMDCs are permissive to MV infection, similar to CD150Tg/*Ifnar*^{-/-} BMDCs. We report here the results of an analysis of CD150Tg/*Mavs*^{-/-} BMDCs in MV infection. Moreover, we show that MV-infected BMDCs induce the differentiation of naïve CD4⁺ T cells into high levels of IL-10- and IFN- γ -producing T cells.

2. Materials and methods

2.1. Mice

All knockout mice were backcrossed with C57BL/6 mice more than eight times before use. CD150Tg (Shinagi et al., 2005), *Ticam1*^{-/-} (Akazawa et al., 2007) and *Mavs*^{-/-} (Oshiumi et al., 2011) mice were generated in our laboratory. *Irf3*^{-/-}/*Irf7*^{-/-} double knockout (DKO) mice (Sato et al., 2000) and IL-10 Venus mice (Atarashi et al., 2011) were provided by Dr. T. Taniguchi (University of Tokyo, Tokyo, Japan) and Dr. K. Honda (RIKEN Research Center for Allergy and Immunology), respectively. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments in the Animal Safety Center, Hokkaido University, Japan. All mice were used according to the guidelines of the Institutional Animal Care and Use Committee of Hokkaido University, who approved this study as no.08-0244. All inoculation and experimental manipulation was performed under anesthesia that was induced and maintained with pentobarbital sodium, and all efforts were made to minimize suffering. All mice were maintained

under specific pathogen-free conditions in the Animal Facility at Hokkaido University Graduate School of Medicine (Sapporo, Japan) and used when they were between 6 and 12 weeks of age.

2.2. Cell culture

Vero/CD150 cells were maintained in DMEM supplemented with 10% heat-inactivated FBS and antibiotics. BMDCs were generated from bone marrow according to the method described by Inaba et al. (1992), with slight modifications. Briefly, bone marrow samples from the femurs and tibiae of mice were cultured in RPMI 1640 (GIBCO) with 10% heat-inactivated FBS containing GM-CSF (J558 supernatant) for 6 days with replenishment of the medium every other day. Splenic naïve CD4⁺ CD25⁻ T cells were isolated by negative selection using the biotin-CD8a, CD11b, B220, Dx5, Gr1, CD25 antibody and streptavidin beads (Miltenyi Biotec) (typically >90% purity) (Akazawa et al., 2007). For coculture experiment, 2 × 10⁵ CD4⁺ T cells and 1 × 10⁴ mock or with MV-infected BMDCs were cocultured with or without anti-CD3 antibody (0.1 μ g/ml) for 4 or 6 days. For restimulation, 4 × 10⁵ CD4⁺ T cells were cultured with the plate bound anti-CD3 antibody (0–1 μ g/ml) for 48 h.

2.3. Virus

IC323, corresponding to the IC-B strain of MV was recovered from the plasmid p(+)MV323 encoding the antigenomic IC-B sequence (Takeda et al., 2000). IC323-Luci (MV-luciferase) was kindly gifted from Dr. M. Takeda (Department of Virology III, National Institute of Infectious Disease, Tokyo, Japan) (Takeda et al., 2007). MV-luciferase and MV-GFP (Shingai et al., 2005) were maintained in Vero/CD150 cells (Shingai et al., 2007). Virus titer was determined as plaque forming units (PFUs) on Vero/CD150 cells and the MOI of each experiment was calculated based on this titer (Kobune et al., 1990). To measure the efficiency of *in vitro* infection, cells (5 × 10⁴ to 2 × 10⁵) were harvested in 25 μ l of lysis buffer for luciferase assays. Luciferase assays were performed using a Dual-Luciferase reporter assay system (Promega), and luciferase activity was read using Lumat LB 9507 (Berthold Technologies). Luciferase activity is shown as means \pm S.D. of three samples.

2.4. *In vivo* infection and BMDCs transfer

Six- to 12-week-old mice were used throughout this study. Mice were infected i.p. with MV-GFP at dose of 1 × 10⁶ pfu. At 3 and 6 days after inoculation, sera were collected from MV- or mock-infected mice. At 4 days after inoculation, CD4⁺ cells, CD8⁺ cells, CD11c⁺ cells and CD19⁺ cells were isolated from splenocytes of MV or mock infected mice using anti-CD4, anti-CD8, anti-CD11c and anti-CD19 MACS beads (Miltenyi Biotec). The purity of isolated cells was >90%. For BMDCs transfer, CD150Tg/*Mavs*^{-/-} BMDCs were infected with MV (MOI=0.25) or mock for 24 h. BMDCs were washed 4 times and resuspended with PBS. Cells (1 × 10⁶ cells) were intravenously transferred to CD150Tg, CD150Tg/*Ifnar*^{-/-} and CD150Tg/*Mavs*^{-/-} mice. After 4 days, splenocytes (1 × 10⁷ cells) and LNs (1 × 10⁷ cells) were collected and CD4⁺ cells, CD8⁺ cells, CD11c⁺ cells and CD19⁺ cells were isolated from the splenocytes. MV titers in these cells were determined by measuring luciferase activity.

2.5. ELISA

Culture supernatants of cells (3–5 × 10⁵) seeded on 24-well plates were collected and analyzed for cytokine levels with enzyme-linked immunosorbent assay (ELISA). ELISA kits for mouse IFN- α and IFN- β were purchased from PBL Biomedical Laboratories. ELISA kits for mouse IL-10, IL-13 and IFN- γ were purchased from

eBiosciences. ELISA was performed according to the manufacturer's instructions.

2.6. RT-PCR and real-time PCR

Total RNA was prepared using TRIzol Reagent (Invitrogen) following the manufacturer's instructions. RT-PCR was carried out using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems) according to the manufacturer's instructions. The nucleotide sequences of the primers for real-time PCR are shown in Supplemental Table 1. Real-time PCR was performed using a Step One real-time PCR system (Applied Biosystems). Expression levels of target mRNA were normalized to β -actin and fold inductions of transcripts were calculated using the ddCT method relative to unstimulated cells.

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.molimm.2013.08.007>.

2.7. FACS analysis

BMDCs were stained with anti-CD11c-APC (eBiosciences) and anti-human CD150-FITC (eBiosciences) and fluorescence intensity was measured by FACS Calibur. For Foxp3 intracellular staining, cells were stained with anti-CD25-PE (eBiosciences), anti-CD4-FITC (eBiosciences) and anti-Foxp3-APC using Foxp3 staining kit (eBiosciences). For IFN- γ intracellular staining, cells were stained with anti-IFN- γ -APC using BD Cytofix/Cytoperm kit (BD Biosciences). Stained cells were analyzed by flow cytometry.

2.8. Statistical analyses

Statistical significance of differences between groups was determined by the Student *t* test using Microsoft Excel software. Values of $p < 0.05$ were considered significant.

3. Results

3.1. CD150Tg/Mavs^{-/-} BMDCs were permissive to MV infection

To identify the induction pathway for the type I IFN response to MV infection, we crossed CD150Tg mice with *Irf3*^{-/-}/*Irf7*^{-/-}, *Ticam1*^{-/-} and *Mavs*^{-/-} mice. First, we measured the expression levels of human CD150 in BMDCs derived from the CD150Tg, CD150Tg/*Irfnar1*^{-/-}, CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-}, CD150Tg/*Ticam1*^{-/-} and CD150Tg/*Mavs*^{-/-} mice using FACS analysis (Fig. 1A). The expression levels of human CD150 were not changed in the BMDCs from any of the CD150Tg/*Irfnar1*^{-/-}, CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-}, CD150Tg/*Ticam1*^{-/-} and CD150Tg/*Mavs*^{-/-} mice (Fig. 1A). In all of the different BMDC genotypes used in this study, human CD150 expression was upregulated in response to LPS and PolyI:C and downregulated by infection with live MV and heated MV (Supplemental Fig. 1). BMDCs were infected with MV-GFP at MOI of 0.25 for 24 h and the percentage of GFP⁺ cells was determined by FACS analysis. While CD150Tg BMDCs were barely permissive to MV compared to mock, ~5% of the CD11c⁺ BMDCs derived from the CD150Tg/*Irfnar1*^{-/-} mice were infected (Fig. 1B). We expected that CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs would be permissive to MV infection, because IRF3 and IRF7 are essential molecules for type I IFN induction in response to viral infection (Sato et al., 2000). However, MV only marginally infected the BMDCs derived from the CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} mice (Fig. 1B). The CD150Tg/*Ticam1*^{-/-} BMDCs were hardly as permissive to MV as CD150Tg BMDCs (Fig. 1B). Approximately 6% of CD150Tg/*Mavs*^{-/-} BMDCs were infected with MV and the infection efficiency in CD150Tg/*Mavs*^{-/-} BMDCs was comparable to that in CD150Tg/*Irfnar1*^{-/-} BMDCs

(Fig. 1B). A previous report suggested that the IFN-inducing pathway in CD11c⁺ BMDCs is critically implicated in establishment of MV infection (Shingai et al., 2005). Here, we show the molecular evidence that MAVS and IFNAR are crucial for protection against MV.

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.molimm.2013.08.007>.

To confirm the efficiency of MV-GFP infection in BMDCs, we used a recombinant MV-luciferase which encodes the reporter *Renilla* luciferase (Takeda et al., 2007). Luciferase activity obtained from MV-infected Vero cells was correlated with the viral titer of MV-infected cells (Supplemental Fig. 2). BMDCs were infected with MV-luciferase at MOI of 0.25 for 24 h and luciferase activity was measured (Fig. 1C). As similar to the results from MV-GFP infection, CD150Tg, and CD150Tg/*Ticam1*^{-/-} BMDCs were not permissive to MV infection compared with CD150Tg/*Irfnar1*^{-/-} BMDCs. On the other hand, a subtle increase of luciferase activity was observed in CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs. Furthermore, the luciferase activity levels obtained from MV-infected CD150Tg/*Irfnar1*^{-/-} and CD150Tg/*Mavs*^{-/-} BMDCs were approximately 2-fold higher than those in CD150Tg BMDCs (Fig. 1C). These data suggest that the loss of MAVS rather than IRF3/7 critically determines MV-permissiveness in CD150Tg BMDCs: *i.e.* an additional transcription factor other than IRF3/7 participates in the protection of CD150Tg BMDCs from MV infection *in vitro*.

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.molimm.2013.08.007>.

3.2. Type I IFN induction rendered CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs MV-nonpermissive

Next, to clarify the reason why MV was barely able to infect CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs, we evaluated type I IFN expression in MV-infected BMDCs (Fig. 2A). As expected, *Ifn- α* mRNA was induced by MV infection in CD150Tg, CD150Tg/*Irfnar1*^{-/-} and CD150Tg/*Ticam1*^{-/-} BMDCs, but not in CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} or CD150Tg/*Mavs*^{-/-} BMDCs (Fig. 2A). IFN- α protein was also induced in CD150Tg, CD150Tg/*Ticam1*^{-/-} BMDCs and to a lesser extent in CD150Tg/*Irfnar1*^{-/-} BMDCs (Fig. 2B). The message-protein discrepancy was observed with IFN- α in MV-infected CD150Tg/*Irfnar1*^{-/-} mice as reported (Marieć et al., 1998). In contrast, *Ifn- β* mRNA expression was observed in CD150Tg, CD150Tg/*Irfnar1*^{-/-}, CD150Tg/*Ticam1*^{-/-} BMDCs and CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs (Fig. 2A). *Ifn- β* was barely detected in CD150Tg/*Mavs*^{-/-} BMDCs. We confirmed the production of the IFN- β protein from MV-infected CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs using ELISA, and found the protein level of IFN- β slightly but firmly detected in the MV-infected *Irf3*^{-/-}/*Irf7*^{-/-} BMDCs (Fig. 2B). This IRF3/IRF7-independent *Ifn- β* induction was almost completely abolished by an NF- κ B inhibitor (BAY11-7082) but not ATF2 inhibitor (SB203580) (Supplemental Fig. 3). These data suggest that IFN- β , but not IFN- α , is induced in CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs in response to MV infection, and then CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs become relatively resistant to MV infection. To examine this possibility, BMDCs derived from mice of various genotypes were infected with MV in the presence of the anti-IFNAR antibody. As expected, MV infected CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs in the presence of the anti-IFNAR antibody (Fig. 2C). The effect of the anti-IFNAR antibody on MV infection in CD150Tg/*Mavs*^{-/-} BMDCs was weak (Fig. 2C). These results were confirmed by using MV-luciferase (Supplemental Fig. 4). These data suggest that MV infection induces IFN- β production in BMDCs in part independent of IRF3/IRF7. In contrast, due to the absence of IFN- α / β induction in the MV-infected CD150Tg/*Mavs*^{-/-} BMDCs (Fig. 2A and B), MV




Fig. 1. CD150Tg/*Mavs*⁻ BMDCs were permissive to MV infection. (A) Expression levels of human CD150 in BMDCs derived from WT, CD150Tg, CD150Tg/*Irf3*⁻/*Irf7*⁻, CD150Tg/*Ticam1*⁻ and CD150Tg/*Mavs*⁻ mice were measured by FACS. The results are representative of three different experiments. (B) BMDCs generated from CD150Tg, CD150Tg/*Irf3*⁻/*Irf7*⁻, CD150Tg/*Ticam1*⁻ and CD150Tg/*Mavs*⁻ mice were infected with MV-GFP (MOI=0.25). At 24 h after infection, the efficiency of virus infection was evaluated by GFP expression using FACS. The numbers indicate the percentages of cells expressing GFP. The results are representative of three different experiments. (C) BMDCs derived from WT, CD150Tg, CD150Tg/*Irf3*⁻/*Irf7*⁻, CD150Tg/*Ticam1*⁻ and CD150Tg/*Mavs*⁻ mice were infected with MV-luciferase (MOI=0.25). At 24 h after infection, the luciferase activity in BMDCs was measured. The data are the means \pm SD of three independent samples. **p* < 0.05, MV-infected CD150Tg BMDCs vs. MV-infected knockout BMDCs.

was able to infect CD150Tg/*Mavs*⁻ BMDCs. Moreover, type I IFN expression in response to MV infection depends on the MAVS pathway in BMDCs.

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.molimm.2013.08.007>.

We next examined whether MV-infected CD150Tg/*Mavs*⁻ BMDCs were able to transmit virus to lymphoid cells *in vivo*. CD150Tg/*Mavs*⁻ BMDCs infected with MV-luciferase (MOI=0.25) were intravenously transferred into CD150Tg,

CD150Tg/*Irf3*⁻/*Irf7*⁻ and CD150Tg/*Mavs*⁻ mice (Fig. 2D). After 4 days, the spleens and lymph nodes (LNs) were harvested and the MV luciferase activity was measured. Luciferase activity was not detected in CD150Tg splenocytes and LNs when mock-infected CD150Tg/*Mavs*⁻ BMDCs were transferred. The luciferase activity in the spleen and LNs was increased when MV-infected CD150Tg/*Mavs*⁻ BMDCs were transferred to CD150Tg mice (Fig. 2D). This result shows that MV-infected CD150Tg/*Mavs*⁻ BMDCs transmit virus to spleen and LN cells in CD150Tg mice. The luciferase activity




Fig. 2. MV infection did not induce type I IFN in CD150Tg/*Mavs*^{-/-} BMDCs. BMDCs derived from WT, CD150Tg, CD150Tg/*Ifnar*^{-/-}, CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-}, CD150Tg/*Ticam1*^{-/-} and CD150Tg/*Mavs*^{-/-} mice were infected with MV-GFP (MOI=0.25) or mock infected. (A) At 24 h after infection, *Ifn-α4* and *Ifn-β* mRNA expression was determined by real-time PCR. The data are the means ± SD of three independent samples. **p* < 0.05, vs. mock-infected. (B) At 24 h after infection, IFN-α and IFN-β in the culture supernatants were measured by ELISA. The data are the means ± SD of three independent samples. **p* < 0.05, vs. mock-infected. (C) BMDCs derived from WT, CD150Tg, CD150Tg/*Ifnar*^{-/-}, CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-}, CD150Tg/*Ticam1*^{-/-} and CD150Tg/*Mavs*^{-/-} mice were infected with MV-GFP (MOI=0.25) or mock infected in the presence or absence of an anti-IFNAR antibody (10 μg/ml). At 24 h after infection, GFP expression was measured by FACS. The numbers shown are the percentages of cells expressing GFP. The results are representative of three different experiments. (D) BMDCs derived from CD150Tg/*Mavs*^{-/-} mice were infected with MV-luciferase (MOI=0.25) or mock infected for 24 h. BMDCs (1 × 10⁶ cells) were washed 4 times and intravenously transferred to CD150Tg, CD150Tg/*Ifnar*^{-/-} and CD150Tg/*Mavs*^{-/-} mice. At 4 days after the transfer, splenocytes and LN cells were collected and measured luciferase activity. Luciferase activity was normalized by the total number of cells. Data are shown as the luciferase activity per 1 × 10⁷ cells. The data are the means ± SD of three independent samples. **p* < 0.05.

obtained from spleens and LNs of CD150Tg/*Irfnar*^{-/-} mice with MV-infected BMDCs was much higher than CD150Tg mice. On the other hand, the efficiency of infection in the spleen and LNs of CD150Tg/*Mavs*^{-/-} mice with MV-infected BMDCs was less than that for CD150Tg/*IFNAR*^{-/-} mice. These results were confirmed with CD19⁺, CD4⁺, CD8⁺ and CD11c⁺ cells isolated from splenocytes (Fig. 2D). These results infer that the spread of MV infection is dependent on IFNAR rather than MAVS in host cells.

3.3. CD4⁺ T cells produced IL-10 when CD4⁺ T cells were cocultured with MV-infected BMDCs

Next, we focused on CD150Tg/*Irfnar*^{-/-} cells because type I IFN induction in response to MV infection is known to be an important determinant of permissiveness to MV. MV infection reportedly induces immunosuppression in humans, non-human primates and mice (Schneider-Schaulies et al., 1995; Moss et al., 2004). DCs are thought to play a pivotal role in the pathogenesis of MV infection and elicit immunosuppressive effects during and after acute MV infection (Schneider-Schaulies et al., 2003; Servet-Delprat et al., 2003). Inducible regulatory T cells (iTreg) have also been reported to participate in immunosuppression during MV infection (Welstead et al., 2005). CD4⁺ T cells prepared from MV-infected CD150Tg/*Irfnar*^{-/-} mice produced the Th2 cytokines, IL-10 and IL-4, and the blocking of IL-10 ameliorated immunosuppression in the MV infected mice (Koga et al., 2010). Therefore, we examined whether MV-infected BMDCs affected Treg induction and the production of cytokines from CD4⁺ T cells. MV-infected CD150Tg/*Irfnar*^{-/-} BMDCs were cocultured with naïve CD4⁺ T cells prepared from wild type (WT) mice for 6 days and then cells were subjected to intracellular staining with an anti-Foxp3 antibody, which is known to be a marker of Treg. Approximately 3% of the CD4⁺ T cells expressed Foxp3, which was comparable to the percentage in naïve CD4⁺ T cells cocultured with uninfected BMDCs (Fig. 3A). Population of CD25⁺ T cells was increased when naïve T cells were cocultured with MV-infected BMDCs (Fig. 3A). A large amount of IL-10 was produced in the supernatant of naïve CD4⁺ T cells cocultured with MV-infected BMDCs and the amount was markedly high compared to that in naïve CD4⁺ T cells cocultured with uninfected BMDCs (Fig. 3B). Moreover, IL-10 production was dependent on anti-CD3 stimulation (Fig. 3B). IFN- γ , a Th1 cytokine, was also detected in the supernatant from naïve CD4⁺ T cells cocultured with MV-infected BMDCs at a level that was comparable to that from naïve CD4⁺ T cells cocultured with uninfected BMDCs (Fig. 3B). To confirm these data, we performed intracellular staining for IL-10 and IFN- γ using IL-10 reporter mice, in which a cassette containing an internal ribosomal entry site and Venus was inserted immediately before the polyadenylation signal of the *Il10* gene (referred to IL-10 Venus mice) (Atarashi et al., 2011). IL-10 Venus⁺ CD4⁺ T cells and IFN- γ ⁺ CD4⁺ T cells were significantly increased when T cells were cocultured with MV-infected BMDCs (Fig. 3C). On the other hand, T cells cocultured with uninfected BMDCs expressed IFN- γ but not IL-10 Venus (Fig. 3C).

We further examined whether these CD4⁺ T cells produced IL-10. BMDCs, either MV-infected or non-infected, were mixed with T cells in anti-CD3-coated wells (Kemper et al., 2003). After 4 days, BMDC/CD4⁺ T-coculture cells were restimulated with plate-bound anti-CD3 antibody for 3 days and the amount of IL-10 and IFN- γ production from CD4⁺ T cells was determined (Fig. 3D). CD4⁺ T cells cocultured with MV-infected BMDCs produced high levels of IL-10 and IFN- γ in a manner that was dependent upon anti-CD3 stimulation (Fig. 3D). Without CD4⁺ T cells, the IL-10 level in the MV-infected BMDCs was not increased compared to the mock-infected BMDCs (Supplemental Fig. 5). This result indicates that MV-infected BMDCs induce the differentiation of naïve CD4⁺ T cells

into IL-10- and IFN- γ -producing T cells. The expression level of *Gata3* mRNA, a master regulator of Th2, was increased when naïve CD4⁺ T cells were cocultured with MV-infected BMDCs (Fig. 3E). *c-Maf* mRNA, a master regulator of Tr1, and *Rorgt* mRNA, a master regulator of Th17, and *Foxp3* mRNAs were decreased in CD4⁺ T cells cocultured with BMDCs (Fig. 3E). The expression level of *Tbet* mRNA, a master regulator of Th1, was increased when naïve CD4⁺ T cells were cocultured with BMDCs (Fig. 3E). Taken together, the results indicate that MV-infected BMDCs affect naïve CD4⁺ T cells in such a manner as to induce IL-10- and IFN- γ -producing T cells without any induction of Treg. Although recent reports have demonstrated that IL-27 promotes IL-10 production by CD4⁺ T cells (Stumhofer et al., 2007; Fitzgerald et al., 2007; Awasthi et al., 2007), in this setting, IL-27 only partially contributed to MV-induced IL-10 production (Supplemental Fig. 6).

Supplementary material related to this article found, in the online version, at <http://dx.doi.org/10.1016/j.molimm.2013.08.007>.

3.4. CD4⁺ T cells produced IL-10 in response to MV infection

The IL-10 level in the serum prepared from MV-infected CD150Tg/*Irfnar*^{-/-} mice was not different from the level in mock-infected mice (Fig. 4A). To identify cell types that produce IL-10, we isolated subsets of the splenocytes from MV- or mock-infected CD150Tg/*Irfnar*^{-/-} mice and restimulated. When CD4⁺ T cells were isolated from MV-infected CD150Tg/*Irfnar*^{-/-} mice, CD4⁺ T cells produced a large amount of IL-10 in response to an anti-CD3 antibody (Fig. 4B) (Kemper et al., 2003). CD8⁺ T cells, CD11c⁺ DCs and CD19⁺ B cells did not produce any evident IL-10 even in the presence of the anti-CD3 antibody, LPS or PMA plus ionomycin, respectively. CD150Tg/*Irfnar*^{-/-} and CD150Tg/IL-10 Venus/*Irfnar*^{-/-} mice were infected with MV. Four days after inoculation, splenocytes were restimulated with PMA, ionomycin and brefeldin A for 6 h and subjected to FACS analysis. IL-10 Venus expression significantly induced in CD4⁺ T cells but not CD8⁺ T cells, CD11c⁺ DCs nor CD19⁺ B cells derived from MV-infected CD150Tg/IL-10 Venus/*Irfnar*^{-/-} mice (Fig. 4C). Moreover, IL-10 producing CD4⁺ T cells were different subsets from IFN- γ producing T cells (Fig. 4D).

4. Discussion

We have demonstrated that CD150Tg/*Mavs*^{-/-} BMDCs were permissive to MV *in vitro*. MV infection did not induce the expression of type I IFN mRNA or protein in CD150Tg/*Mavs*^{-/-} BMDCs. These data suggest that MV-derived primary type I IFN depends on the MAVS pathway in BMDCs, the result being consistent with the fact that CD11c⁺ DCs are a primary target for replication of MV (Shingai et al., 2005).

Unexpectedly, MV infection minimally occurred in BMDCs prepared from CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} mice, because of their capacity to produce IFN- β . When anti-IFNAR antibody was present, MV was able to infect CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs. Therefore, MV-induced type I IFN production depends on not only the primary MAVS-IRF3/7 pathway but also the amplifiable IFNAR pathway in BMDCs, and that unidentified transcription factors, rather than IRF3/IRF7, participate in the primary induction of IFN- β . TLR3 signals the presence of exogenous RNA via the TICAM-1 adaptor (Oshiumi et al., 2003). Although TLR3/TICAM-1 participate in BMDC maturation in response to cell-derived virus RNA in RNA virus infections (Ebihara et al., 2008; Oshiumi et al., 2011), this is not the case in MV infection.

Ifn- β is reportedly induced in conjunction with the activation of transcription factors, IRF3, IRF7, ATF-2/c-Jun and NF- κ B




Fig. 3. MV-infected BMDCs induced IL-10 and IFN- γ producing CD4⁺ T cells. CD150Tg/*Irfar-1*^{-/-} BMDCs were infected with MV (MOI=0.25) or mock for 24 h. Naïve CD4⁺CD25⁻ T cells (2×10^5) isolated from WT mice were cocultured with 1×10^4 BMDCs in the presence or absence of 0.1 μ g/ml of the anti-CD3 antibody. (A) At 6 days after coculture, cells were stained with anti-CD4, anti-CD25 and anti-Foxp3 antibodies and subjected to FACS analysis. The numbers shown are the percentage of CD25⁺Foxp3⁺ cells. The results are representative of three different experiments. (B) At 4 or 6 days after coculture, IL-10 and IFN- γ in the culture supernatant were measured by ELISA. The data are the means \pm SD of three independent samples. * $p < 0.05$. (C) CD4⁺ T cells isolated from IL-10 Venus mice were cocultured with uninfected or MV-infected CD150Tg/*Irfar-1*^{-/-} BMDCs for 4 days. Cells were stained with anti-CD3, anti-CD4 and anti-IFN- γ antibodies and analyzed by flow cytometry. The numbers shown are the percentage of CD4⁺IL-10 Venus⁺ cells and CD4⁺IFN- γ ⁺ cells. The right graphs represent the fraction of the IL-10 Venus⁺ cell and IFN- γ ⁺ cell populations. The data are the means \pm SD of three independent samples. * $p < 0.05$. (D) At 4 days after the coculture, cells were collected and washed twice. Two $\times 10^5$ cells were restimulated with the anti-CD3 plate-bound antibody for 3 days. At 3 days after restimulation, IL-10 and IFN- γ in the culture supernatants were measured by ELISA. The data are the means \pm SD of three independent samples. * $p < 0.05$. (E). At 4 days after the coculture, the expression level of *c-Maf*, *T-bet*, *Gata-3*, *Rorgt* and *Foxp3* mRNA in the CD4⁺ T cells cocultured with MV- or mock-infected BMDCs were determined by real-time PCR. The data are the means \pm SD of three independent samples. N.S.; not significant, * $p < 0.05$.




Fig. 4. CD4⁺ T cells produced IL-10 *ex vivo*. (A) CD150Tg/*Ifnar*^{-/-} mice were infected i.p. with 1 × 10⁶ pfu MV-GFP or mock. At the indicated days after infection, IL-10 production in sera was measured by ELISA. The data are the means ± SD of three independent samples. N.S.; not significant. (B) CD150Tg/*Ifnar*^{-/-} mice were infected i.p. with 1 × 10⁶ pfu MV-GFP or mock infected. At 4 days after infection, CD4⁺, CD8⁺, CD11c⁺ and CD19⁺ cells were isolated from splenocytes and restimulated with plate-bound anti-CD3 (0–1.0 μg/ml), LPS (100 ng/ml) or PMA (1 μg/ml) plus ionomycin (1 μg/ml) (P+I), respectively. At 3 days after restimulation, IL-10 production in the culture supernatant was measured by ELISA. The data are the means ± SD of three independent samples. **p* < 0.05. (C, D) CD150Tg/*Ifnar*^{-/-} and CD150Tg/IL-10Venus/*Ifnar*^{-/-} mice were infected with MV (1 × 10⁶ pfu). At 2 days after inoculation, splenocytes were stained with anti-CD3, anti-CD4, anti-CD8, anti-CD11c, anti-CD19, and anti-IFN-γ antibodies and subjected to FACS analysis. (C) The numbers shown are the percentage of IL-10⁺ cells. (D) The numbers shown are the percentage of the gated populations. The results are representative of three different experiments.

(Thanos and Maniatis, 1995; Panne et al., 2007). The coordinated binding of these regulatory factors synergistically augments transcription of the *Ifn-β* gene in several different cell types (Thanos and Maniatis, 1995). MAVS-dependent IRF3/IRF7-bypassed *Ifn-β* induction has also been reported to take place through the NF-κB signaling pathway in West Nile virus infection, the case being not only for DCs (Daffis et al., 2009). Recently, the MAVS/IRF5-dependent pathway was identified to participate in type I IFN induction in West Nile virus-infected myeloid cells BMDCs (Lazear et al., 2013). IRF1 is also involved in TLR9-mediated IFN-β production in BMDCs (Schmitz et al., 2007). In the case of MV infection, IRF5 and IRF1 might be candidate transcription factors for MAVS-dependent and IRF3/IRF7-independent type I IFN induction in BMDCs.

In this context, we looked for possible transcription factors other than typical IRFs. We found from a pharmacological test that the treatment of CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} BMDCs with an NF-κB inhibitor (BAY11-7082) resulted a significant reduction of MV-induced *Ifn-β* mRNA expression (Supplemental Fig. 3), suggesting that NF-κB is involved in MV-induced type I IFN expression in BMDCs. The result infers that MV mouse models harbor multiple IFN-inducing pathways and the MAVS-NF-κB axis predominantly functions in transferred BMDCs even with no IRF3/IRF7 for protection against MV infection in mice. Yet, the possible participation of IRF1 or IRF5 in NF-κB-mediated type I IFN induction has remained to be determined. This MAVS-NF-κB-mediated IFN-β induction and resultant protection against MV spread is unique to mouse BMDCs: other immune cells are protected from MV by IFNAR-STAT signaling

in the MV-infected BMDC transfer system (Shingai et al., 2005). The result reflects the essential protective role of IFNAR (that is activated by primary MAVS-derived IFN- β) from establishing systemic MV infection in mouse models (Welstead et al., 2005; Shingai et al., 2005; Sellin et al., 2009; Koga et al., 2010).

Each successful virus species has developed its own means of circumventing the host IFN system, and the RNA-sensing system was developed in the course of stepwise mutation of the viral genomes. In an earlier study, RIG-I and MDA5 were reported to be sensors for RNA structures characteristic of virus species (Kato et al., 2006). This concept was adapted to MV in human epithelial cells (Ikegame et al., 2010). However, these typical cases appear rather rare in *in vivo* virus infections, which are more complicated than the situation found in RIG-I/MDA5 knockout mice (Kato et al., 2006), depending upon the host tropism, phases and stages of virus infection. *In vivo*, RIG-I and MDA5 in epithelial cells are implicated in the formation of an infectious milieu and type I IFN production in laboratory-adapted or genetically-mutated MV strains (Takaki et al., 2011; Shingai et al., 2005), but there appears to be no *in vivo* data supporting this finding. In general, each cell type has its own dominant IFN-inducing systems by which viral infections are differentially sensed and rapidly prevented in a cell-specific manner. Here, we show that the MAVS-dependent but IRF-3/7-independent IFN- β production actually does function in CD150Tg BMDCs in response to MV infection, this pathway being unique to BMDCs for primary MV protection. Secondary protection against MV spreading to other cells is accomplished by IFNAR which prevents systemic MV infection due to BMDCs transfer. There are a number of subsets in mouse DCs, which differentially respond to MV with their IFN-inducing pathways (Takaki et al., 2013). It will be of interest to determine whether the results are reproducible in other DC subsets in the mouse MV-infection model.

In patients with measles, alteration of the cytokine profile has been reported earlier (Griffin et al., 1990). The early Th1 response is shifted to a Th2 response, which occurs during the late stages of measles, with an increase in the secretion of IL-4 and a decrease in the IL-12 levels (Naniche and Oldstone, 2000; Atabani et al., 2001). Consistent with these reports, we detected a high level of IL-13 production in the coculture supernatant of CD4⁺ T cells and MV-infected BMDCs (data not shown). The plasma level of the anti-inflammatory cytokine IL-10 is increased in patients with measles (Atabani et al., 2001; Yu et al., 2008). This elevated level of plasma IL-10 probably contributes to the impaired cellular immunity and depressed hypersensitivity response following MV infection (Ryon et al., 2002). However, the primary DC response and source of IL-10 in MV-infected patients is at present not clear.

Recently a study reported that IL-10 is the cause of MV-induced immunosuppression in MV-infectious model mice (Koga et al., 2010). However, during MV infection, both the cells which produce IL-10 and the induction mechanism of IL-10 in these cells have yet to be elucidated. In this report, we showed that CD4⁺ T cells are one of the cell types that produce IL-10 in response to MV infection both *ex vivo* and *in vitro*. MV-infected BMDCs induce IL-10- and IFN- γ -producing CD4⁺ T cells, but not Treg cells. Previous reports showed that T regulatory (Tr1) cells became IL-10 and IFN- γ producing CD4⁺ T cells (Vieira et al., 2004; Roncarolo et al., 2006), and that Tr1 cells in concert with IL-10-producing DCs were indispensable for a high level of IL-10 (Roncarolo et al., 2006). However, in Fig. 4A, IL-10 was neither produced in BMDCs nor up-regulated in mouse sera irrespective of MV-infection. It is CD4⁺ T cells that produce IL-10 in response to MV and CD3 stimulation (Fig. 4B).

Recent reports have demonstrated that IL-27 promotes IL-10 production by CD4⁺ T cells (Stumhofer et al., 2007; Fitzgerald et al., 2007; Awasthi et al., 2007), and the induction of c-Maf, IL-21 and ICOS has been proposed as a mechanism of IL-27-mediated Tr1 cell differentiation (Pot et al., 2009). We examined whether

IL-27 was involved in MV-induced IL-10 and IFN- γ production in CD4⁺ T cells with an anti-IL-27p28 neutralizing antibody. Blocking IL-27p28 partially suppressed IL-10 production in CD4⁺ T cells which had been cocultured with MV-infected BMDCs (Supplemental Fig. 6), indicating that IL-27 might participate in the mechanisms of induction of MV-mediated Tr1-like cells *in vitro*.

CD150Tg/*Mavs*^{-/-} BMDCs completely lack the ability to produce type I IFN, and thereby are permissive to MV infection (Fig. 2A and B). CD150Tg/*Ifnar*^{-/-} mice have the full capacity to produce IFN- β in MV infection, but cannot compensate for the IFNAR-null state in BMDCs. The artificial unresponsiveness of the IFN amplification pathway to MV infection may have caused unusual immune aberrations (Welstead et al., 2005; Shingai et al., 2005; Sellin et al., 2009; Koga et al., 2010) due to the absence of any "idling" production of type I IFN in these gene-disrupted mice (Takaoka and Taniguchi, 2003). It would be likely that a lack of the amplification pathway of type I IFN also confers MV permissiveness on BMDCs in mice, even though the mice have intact MAVS pathway to produce sufficient IFN- β . The present analysis of CD150Tg/*Mavs*^{-/-} BMDCs in MV infection allowed us to highlight the molecular mechanisms of initial type I IFN induction and IL-10 production by CD4⁺ T cells in a mouse model. Further analyses using the model will contribute to elucidation of possible mechanisms by which MV induces immune modulation.

Conflict of interest

There is no declared conflict of interest in this study.

Acknowledgements

We are grateful to Dr. Taniguchi (University of Tokyo) for providing *Irf3*^{-/-} and *Irf7*^{-/-} mice and Dr. Honda (RIKEN Research Center for Allergy and Immunology) for providing IL-10 Venus mice for this study. We also thank to Dr. Y. Yanagi (Kyushu University) for providing MV-luciferase. This work was supported in part by Grants-in-Aid from the Ministry of Education, Science, and Culture (Specified Project for Advanced Research) and the Ministry of Health, Labor, and Welfare of Japan, and by the Ono Foundation and the Itoh Foundation. Financial supports by the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases, MEXT, is gratefully acknowledged.

References

- Akazawa, T., Ebihara, T., Okuno, M., Okuda, Y., Shingai, M., Tsujimura, K., Takahashi, T., Ikawa, M., Okabe, M., Inoue, N., Okamoto-Tanaka, M., Ishizaki, H., Miyoshi, J., Matsumoto, M., Seya, T., 2007. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. *Proc. Natl. Acad. Sci. U. S. A.* 104, 252–257, <http://dx.doi.org/10.1073/pnas.0605978104>.
- Atabani, S.F., Byrnes, A.A., Jaye, A., Kidd, I.M., Magnusen, A.F., Whittle, H., Karp, C.L., 2001. Natural measles causes prolonged suppression of interleukin-12 production. *J. Infect. Dis.* 184, 1–9, <http://dx.doi.org/10.1086/321009>.
- Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T., Ohba, Y., Taniguchi, T., Takeda, K., Hori, S., Ivanov, I.I., Umesaki, Y., Itoh, K., Honda, K., 2011. Induction of colonic regulatory T cells by indigenous Clostridium species. *Science* 331, 337–341, <http://dx.doi.org/10.1126/science.1198469>.
- Awasthi, A., Carrier, Y., Peron, J.P., Bettelli, E., Kamanaka, M., Flavell, R.A., Kuchroo, V.K., Oukka, M., Weiner, H.L., 2007. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. *Nat. Immunol.* 8, 1380–1389, <http://dx.doi.org/10.1038/ni1541>.
- Daffis, S., Suthar, M.S., Szretter, K.J., Gale M.Jr., Diamond, M.S., 2009. Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7. *PLoS Pathog.* 5, e1000607, <http://dx.doi.org/10.1371/journal.ppat.1000607>.
- Ebihara, T., Shingai, M., Matsumoto, M., Wakita, T., Seya, T., 2008. Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. *Hepatology* 48 (July (1)), 48–58, <http://dx.doi.org/10.1002/hep.22337>.
- Fitzgerald, D.C., Zhang, G.X., El-Behi, M., Fonseca-Kelly, Z., Li, H., Yu, S., Saris, C.J., Gran, B., Ciric, B., Rostami, A., 2007. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. *Nat. Immunol.* 8, 1372–1379, <http://dx.doi.org/10.1038/ni1540>.

- Fugier-Vivier, I., Servet-Delprat, C., Rivaller, P., Rissoan, M.C., Liu, Y.J., Rabourdin-Combe, C., 1997. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. *J. Exp. Med.* 186, 813–823, <http://dx.doi.org/10.1084/jem.186.6.813>.
- Griffin, D.E., Ward, B.J., Jauregui, E., Johnson, R.T., Vaisberg, A., 1990. Immune activation during measles: interferon-gamma and neopterin in plasma and cerebrospinal fluid in complicated and uncomplicated disease. *J. Infect. Dis.* 161, 449–453.
- Grosjean, I., Caux, C., Bella, C., Berger, I., Wild, F., Banchereau, J., Kaiserlian, D., 1997. Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4⁺ T cells. *J. Exp. Med.* 186, 801–812, <http://dx.doi.org/10.1084/jem.186.6.801>.
- Honda, K., Takaoka, A., Taniguchi, T., 2006. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. *Immunity* 25, 349–360.
- Ikegame, S., Takeda, M., Ohno, S., Nakatsu, Y., Nakanishi, Y., Yanagi, Y., 2010. Both RIG-I and MDA5 RNA helicases contribute to the induction of alpha/beta interferon in measles virus-infected human cells. *J. Virol.* 84, 372–379, <http://dx.doi.org/10.1128/JVI.01690-09>.
- Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., Steinman, R.M., 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J. Exp. Med.* 176, 1693–1702.
- Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K.J., Yamaguchi, O., Otsu, K., Tsujimura, T., Koh, C.S., Reis e Sousa, C., Matsuura, Y., Fujita, T., Akira, S., 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* 441, 101–105, <http://dx.doi.org/10.1038/nature04734>.
- Kawai, T., Akira, S., 2006. Innate immune recognition of viral infection. *Nat. Immunol.* 7, 131–137.
- Kemper, C., Chan, A.C., Green, J.M., Brett, K.A., Murphy, K.M., Atkinson, J.P., 2003. Activation of human CD4⁺ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. *Nature* 421, 388–392, <http://dx.doi.org/10.1038/nature01315>.
- Koga, R., Ohno, S., Ikegame, S., Yanagi, Y., 2010. Measles virus-induced immunosuppression in SLAM knock-in mice. *J. Virol.* 84, 5360–5367, <http://dx.doi.org/10.1128/JVI.02525-09>.
- Kobune, F., Sakata, H., Hayashi, T., 1990. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. *J. Virol.* 64, 700–705.
- Lazear, H.M., Lancaster, A., Wilkins, C., Suthar, M.S., Huang, A., Vick, S.C., Clepper, L., Thackray, L., Brassil, M.M., Virgin, H.W., Nikolich-Zugich, J., Moses, A.V., Gale Jr., M., Früh, K., Diamond, M.S., 2013. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. *PLoS Pathog.* 9 (1), e1003118, <http://dx.doi.org/10.1371/journal.ppat.1003118>.
- Marie, I., Durbin, J.E., Levy, D.E., 1998. Differential viral induction of distinct interferon- α genes by positive feedback through interferon regulatory factor-7. *EMBO J.* 17, 6660–6669.
- Matsumoto, M., Oshiumi, H., Seya, T., 2011. Antiviral responses induced by the TLR3 pathway. *Rev. Med. Virol.* 21, 67–77, <http://dx.doi.org/10.1002/rmv.680>.
- Moss, W.J., Ota, M.O., Griffin, D.E., 2004. Measles: immune suppression and immune responses. *Int. J. Biochem. Cell Biol.* 36, 1380–1385, <http://dx.doi.org/10.1016/j.biocel.2004.01.019>.
- Murabayashi, N., Kurita-Taniguchi, M., Ayata, M., Matsumoto, M., Ogura, H., Seya, T., 2002. Susceptibility of human dendritic cells (DCs) to measles virus (MV) depends on their activation stages in conjunction with the level of CDw150: role of Toll stimulators in DC maturation and MV amplification. *Microbe. Infect.* 4, 785–794.
- Naniche, D., Oldstone, M.B., 2000. Generalized immunosuppression: how viruses undermine the immune response. *Cell. Mol. Life Sci.* 57, 1399–1407, <http://dx.doi.org/10.1007/PL00000625>.
- Ohno, S., Ono, N., Takeda, M., Takeuchi, K., Yanagi, Y., 2004. Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. *J. Gen. Virol.* 85, 2991–2999, <http://dx.doi.org/10.1099/vir.0.80308-0>.
- Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., Seya, T., 2003. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. *Nat. Immunol.* 4, 161–167, <http://dx.doi.org/10.1038/ni886>.
- Oshiumi, H., Okamoto, M., Fujii, K., Kawanishi, T., Matsumoto, M., Koike, S., Seya, T., 2011. The TLR3/TICAM-1 pathway is mandatory for innate immune responses to poliovirus infection. *J. Immunol.* 187, 5320–5327, <http://dx.doi.org/10.4049/jimmunol.1101503>.
- Panne, D., Maniatis, T., Harrison, S.C., 2007. An atomic model of the interferon-beta enhancosome. *Cell* 129, 1111–1123, <http://dx.doi.org/10.1016/j.cell.2007.05.019>.
- Pot, C., Jin, H., Awasthi, A., Liu, S.M., Lai, C.Y., Madan, R., Sharpe, A.H., Karp, C.L., Miaw, S.C., Ho, I.C., Kuchroo, V.K., 2009. IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. *J. Immunol.* 183, 797–801, <http://dx.doi.org/10.4049/jimmunol.0901233>.
- Radecke, F., Spielhofer, P., Schneider, H., Kaelin, K., Huber, M., Dötsch, C., Christiansen, G., Billeter, M.A., 1995. Rescue of measles viruses from cloned DNA. *EMBO J.* 14, 5773–5784.
- Rathinam, V.A., Fitzgerald, K.A., 2011. Cytosolic surveillance and antiviral immunity. *Curr. Opin. Virol.* 1, 455–462, <http://dx.doi.org/10.1016/j.coviro.2011.11.004>.
- Roncarolo, M.G., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., Levings, M.K., 2006. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. *Immunol. Rev.* 212, 28–50, <http://dx.doi.org/10.1111/j.0105-2896.2006.00420.x>.
- Ryon, J.J., Moss, W.J., Monze, M., Griffin, D.E., 2002. Functional and phenotypic changes in circulating lymphocytes from hospitalized Zambian children with measles. *Clin. Diagn. Lab. Immunol.* 9, 994–1003, <http://dx.doi.org/10.1128/CDLI.9.5.994-1003.2002>.
- Sato, M., Suemori, H., Hata, N., Asagiri, M., Ogasawara, K., Nakao, K., Nakaya, T., Katsuki, M., Noguchi, S., Tanaka, N., Taniguchi, T., 2000. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN- α/β gene induction. *Immunity* 13, 539–548, [http://dx.doi.org/10.1016/S1074-7613\(00\)0053-4](http://dx.doi.org/10.1016/S1074-7613(00)0053-4).
- Schmitz, F., Heit, A., Guggemoos, S., Krug, A., Mages, J., Schiemann, M., Adler, H., Drexler, I., Haas, T., Lang, R., Wagner, H., 2007. Interferon-regulatory factor 1 controls Toll-like receptor 9-mediated IFN-beta production in myeloid dendritic cells. *Eur. J. Immunol.* 37, 315–327.
- Schneider-Schaulies, J., Dunster, L.M., Schneider-Schaulies, S., ter Meulen, V., 1995. Pathogenetic aspects of measles virus infections. *Vet. Microbiol.* 44, 113–125, [http://dx.doi.org/10.1016/0378-1135\(95\)00004-T](http://dx.doi.org/10.1016/0378-1135(95)00004-T).
- Schneider-Schaulies, S., Klagge, I.M., ter Meulen, V., 2003. Dendritic cells and measles virus infection. *Curr. Top Microbiol. Immunol.* 276, 77–101, <http://dx.doi.org/10.1007/978-3-662-06508-2.4>.
- Sellin, C.L., Jégou, J.F., Renneson, J., Druelle, J., Wild, T.F., Marie, J.C., Horvat, B., 2009. Interplay between virus-specific effector response and Foxp3 regulatory T cells in measles virus immunopathogenesis. *PLoS ONE* 4, e4948, <http://dx.doi.org/10.1371/journal.pone.0004948>.
- Servet-Delprat, C., Vidalain, P.O., Valentin, H., Rabourdin-Combe, C., 2003. Measles virus and dendritic cell functions: how specific response cohabits with immunosuppression. *Curr. Top Microbiol. Immunol.* 276, 103–123, <http://dx.doi.org/10.1007/978-3-662-06508-2.5>.
- Shingai, M., Inoue, N., Okuno, T., Okabe, M., Akazawa, T., Miyamoto, Y., Ayata, M., Honda, K., Kurita-Taniguchi, M., Matsumoto, M., Ogura, H., Taniguchi, T., Seya, T., 2005. Wild-type measles virus infection in human CD46/CD150-transgenic mice: CD11c-positive dendritic cells establish systemic viral infection. *J. Immunol.* 175, 3253–3261.
- Shingai, M., Ebihara, T., Begum, N.A., Kato, A., Honma, T., Matsumoto, K., Saito, H., Ogura, H., Matsumoto, M., Seya, T., 2007. Differential type I IFN-inducing abilities of wild-type versus vaccine strains of measles virus. *J. Immunol.* 179, 6123–6133.
- Stumhofer, J.S., Silver, J.S., Laurence, A., Porrett, P.M., Harris, T.H., Turka, L.A., Ernst, M., Saris, C.J., O'Shea, J.J., Hunter, C.A., 2007. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. *Nat. Immunol.* 8, 1363–1371, <http://dx.doi.org/10.1038/ni1537>.
- Takaki, H., Watanabe, Y., Shingai, M., Oshiumi, H., Matsumoto, M., Seya, T., 2011. Strain-to-strain difference of V protein of measles virus affects MDA5-mediated IFN- β -inducing potential. *Mol. Immunol.* 48, 497–504, <http://dx.doi.org/10.1016/j.molimm.2010.10.006>.
- Takaki, H., Takeda, M., Tahara, M., Shingai, M., Oshiumi, H., Matsumoto, M., Seya, T., 2013. MyD88 pathway in plasmacytoid and CD4⁺ dendritic cells primarily triggers type I IFN production against measles virus in a mouse infection model. *J. Immunol.* (in press).
- Takaoka, A., Taniguchi, T., 2003. New aspects of IFN-alpha/beta signalling in immunity, oncogenesis and bone metabolism. *Cancer Sci.* 94, 405–411, <http://dx.doi.org/10.1111/j.1349-7006.2003.tb01455.x>.
- Takeda, M., Takeuchi, K., Miyajima, N., Kobune, F., Ami, Y., Nagata, N., Suzuki, Y., Nagai, Y., Tashiro, M., 2000. Recovery of pathogenic measles virus from cloned cDNA. *J. Virol.* 74, 6643–6647.
- Takeda, M., Tahara, M., Hashiguchi, T., Sato, T.A., Jinnouchi, F., Ueki, S., Ohno, S., Yanagi, Y., 2007. A human lung carcinoma cell line supports efficient measles virus growth and syncytium formation via a SLAM- and CD46-independent mechanism. *J. Virol.* 81, 12091–12096, <http://dx.doi.org/10.1128/JVI.01264-07>.
- Takeuchi, K., Kadota, S.I., Takeda, M., Miyajima, N., Nagata, K., 2003. Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation. *FEBS Lett.* 545, 177–182.
- Tanabe, M., Kurita-Taniguchi, M., Takeuchi, K., Takeda, M., Ayata, M., Ogura, H., Matsumoto, M., Seya, T., 2003. Mechanism of up-regulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains. *Biochem. Biophys. Res. Commun.* 311, 39–48.
- Tatsuo, H., Ono, N., Tanaka, K., Yanagi, Y., 2000. SLAM (CDw150) is a cellular receptor for measles virus. *Nature* 406, 893–897.
- Thanos, D., Maniatis, T., 1995. Virus induction of human IFN beta gene expression requires the assembly of an enhancosome. *Cell* 83, 1091–1100, [http://dx.doi.org/10.1016/0092-8674\(95\)90136-1](http://dx.doi.org/10.1016/0092-8674(95)90136-1).
- Vieira, P.L., Christensen, J.R., Minaee, S., O'Neill, E.J., Barrat, F.J., Boonstra, A., Barthlott, T., Stockinger, B., Wraith, D.C., O'Garra, A., 2004. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4⁺ CD25⁺ regulatory T cells. *J. Immunol.* 172, 5986–5993.
- Welstead, G.G., Iorio, C., Draker, R., Bayani, J., Squire, J., Vongpunsawad, S., Cattaneo, R., Richardson, C.D., 2005. Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice. *Proc. Natl. Acad. Sci. U.S.A.* 102, 16415–16420, <http://dx.doi.org/10.1073/pnas.0505945102>.
- Yoneyama, M., Onomoto, K., Fujita, T., 2008. Cytoplasmic recognition of RNA. *Adv. Drug. Deliv. Rev.* 60, 841–846, <http://dx.doi.org/10.1016/j.addr.2007.12.001>.
- Yu, X.L., Cheng, Y.M., Shi, B.S., Qian, F.X., Wang, F.B., Liu, X.N., Yang, H.Y., Xu, Q.N., Qi, T.K., Zha, L.J., Yuan, Z.H., Ghildyal, R., 2008. Measles virus infection in adults induces production of IL-10 and is associated with increased CD4⁺ CD25⁺ regulatory T cells. *J. Immunol.* 181, 7356–7366.

The MyD88 Pathway in Plasmacytoid and CD4⁺ Dendritic Cells Primarily Triggers Type I IFN Production against Measles Virus in a Mouse Infection Model

Hiromi Takaki,* Makoto Takeda,[†] Maino Tahara,[†] Masashi Shingai,*¹ Hiroyuki Oshiumi,* Misako Matsumoto,* and Tsukasa Seya*

Infection by measles virus (MV) induces type I IFN via the retinoic acid–inducible gene I/melanoma differentiation–associated gene 5/mitochondrial antiviral signaling protein (MAVS) pathway in human cells. However, the *in vivo* role of the MAVS pathway in host defense against MV infection remains undetermined. CD150 transgenic (Tg) mice, which express human CD150, an entry receptor for MV, with the disrupting IFNR gene (*Ifnar*^{−/−}), are susceptible to MV and serve as a model for MV infection. In this study, we generated CD150Tg/*Mavs*^{−/−} mice and examined MV permissiveness compared with that in CD150Tg/*Ifnar*^{−/−} mice. MV replicated mostly in the spleen of i.p.-infected CD150Tg/*Ifnar*^{−/−} mice. Strikingly, CD150Tg/*Mavs*^{−/−} mice were not permissive to MV *in vivo* because of substantial type I IFN induction. MV barely replicated in any other organs tested. When T cells, B cells, and dendritic cells (DCs) isolated from CD150Tg/*Mavs*^{−/−} splenocytes were cultured with MV *in vitro*, only the DCs produced type I IFN. *In vitro* infection analysis using CD150Tg/*Mavs*^{−/−} DC subsets revealed that CD4⁺ and plasmacytoid DCs, but not CD8α⁺ and CD8α[−]CD4[−] double negative DCs, were exclusively involved in type I IFN production in response to MV infection. Because CD150Tg/*Mavs*^{−/−} mice turned permissive to MV by anti-IFNAR Ab, type I IFN produced by CD4⁺ DCs and plasmacytoid DCs plays a critical role in antiviral protection for neighboring cells expressing IFNAR. Induction of type I IFN in these DC subsets was abolished by the MyD88 inhibitory peptide. Thus, production of type I IFN occurs via the MyD88-dependent and MAVS-independent signaling pathway during MV infection. *The Journal of Immunology*, 2013, 191: 4740–4747.

Type I IFNs (IFN-α/β) are crucial for protection against viral infections (1). Viral RNA is detected by cytosolic RNA sensors and induces expression of type I IFN (2). Extracellular dsRNA of a virus product is detected by the endosomal TLR3, whereas intracellular dsRNA is sensed by the retinoic acid–inducible gene I (RIG-I) and the melanoma differentiation–associated gene 5 (MDA5) (3). Upon recognizing dsRNA, TLR3 recruits the Toll/IL-1R (TIR) homology domain–containing adaptor

molecule 1 (TICAM-1, also referred to as TRIF) and induces type I IFN production (4, 5). The RIG-I-like receptors (RLRs), RIG-I and MDA5, signal via the mitochondrial antiviral signaling protein (MAVS; also known as VISA, Cardif, or IPS-1) and also induce type I IFN expression (6). Knocking out these adaptor molecules results in failure to activate the transcription factors IFN regulatory factor (IRF)-3 and IRF-7, leading to an incompetence in type I IFN production and antiviral host defense (3, 7, 8). Type I IFN induction following the recognition of measles virus (MV) RNA is dependent on the RIG-I/MDA5–MAVS pathway in human epithelial cell lines (9, 10). However, the role of the RIG-I/MDA5–MAVS pathway during *in vivo* MV infection remains undetermined.

MV, of the genus *Morbillivirus* from the Paramyxoviridae family, is a highly pathogenic, nonsegmented negative single-stranded RNA virus that causes respiratory distress and immunosuppression in humans (11). Wild-type strains of MV enter cells via human CD150, which is also referred to as signaling lymphocyte activation molecule (12), and human poliovirus receptor–like protein 4 (13, 14). Expression of these receptors is restricted either to activated lymphocytes, dendritic cells (DCs), and macrophages for CD150 or to the basolateral surface of epithelial cells for PVRL4 (15). Among these cell populations, CD11c⁺ DCs and alveolar macrophages (AMs) are reported to be the first target cells of early-phase MV infection in the CD150 transgenic (Tg) mouse model (16, 17) and in nonhuman primates (18, 19). Moreover, DCs are found to be involved in pathogenesis and immunosuppression during and after acute MV infection (20, 21). However, it is unclear how DCs and macrophages recognize MV RNA to produce type I IFN.

Human CD150Tg mice, which are slightly permissive to MV, are used to study host responses against MV infection *in vivo* (16, 22–24). CD150Tg/*Ifnar*^{−/−} mice, which are generated by crossing CD150Tg mice with *Ifnar*^{−/−} mice, are susceptible to MV infection

*Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo 060-8638, Japan; and [†]Department of Virology 3, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo 208-0011, Japan

¹Current address: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Received for publication July 3, 2013. Accepted for publication August 28, 2013.

This work was supported in part by grants-in-aid from the Ministry of Education, Science, and Culture (Specified Project for Advanced Research) and the Ministry of Health, Labor, and Welfare of Japan; the Japan Society for the Promotion of Science Fellows and Support Office for Female Researchers in Hokkaido University; the Takeda Foundation and the Waxmann Foundation; and the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases, Ministry of Education, Culture, Sports, Science and Technology.

Address correspondence and reprint requests to Prof. Tsukasa Seya and Dr. Hiromi Takaki, Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan. E-mail addresses: seya-tu@pop.med.hokudai.ac.jp (T.S.) and tahiromi@sci.hokudai.ac.jp (H.T.)

The online version of this article contains supplemental material.

Abbreviations used in this article: AM, alveolar macrophage; BMDC, bone marrow–derived DC; cDC, conventional DC; DC, dendritic cell; DN, double negative; IRF, IFN regulatory factor; LN, lymph node; MAVS, mitochondrial antiviral signaling protein; MDA5, melanoma differentiation–associated gene 5; MOI, multiplicity of infection; MV, measles virus; MyD88, myeloid differentiation factor 88; pDC, plasmacytoid DC; PDCA-1, pDC Ag 1; RIG-I, retinoic acid–inducible gene I; RLR, RIG-I–like receptor; Tg, transgenic; TICAM-1, Toll/IL-1R homology domain–containing adaptor molecule 1; TIR, Toll/IL-1R.

Copyright © 2013 by The American Association of Immunologists, Inc. 0022-1767/13/\$16.00

and serve as a useful mouse model (16, 24). In the current study, using the CD150Tg mouse model in combination with *Mavs*^{-/-}, *Irf3*^{-/-}/*Irf7*^{-/-}, and *Ticam1*^{-/-} mice, we found that CD150Tg/*Mavs*^{-/-} mice were not permissive to MV in vivo, whereas CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-} mice were permissive. Furthermore, CD150Tg/*Mavs*^{-/-} plasmacytoid DCs (pDCs) and CD4⁺ DCs produced type I IFN in response to MV infection in vitro. Analysis using the myeloid differentiation factor 88 (MyD88) inhibitory peptide and MyD88^{-/-} mice revealed that type I IFN production in these DC subsets was dependent on the MyD88 pathway. To our knowledge, this is the first study to show that type I IFN induction in MV-infected mouse DCs depends on the MyD88 pathway. The properties of the MV-permissive mouse DC subsets may be crucial for ensuring immune response, including immunosuppression during MV infection.

Materials and Methods

Mice

All mice were backcrossed to C57BL/6 mice more than eight times before use. CD150Tg (16), *Ticam1*^{-/-} (25), and *Mavs*^{-/-} (26) mice were generated in our laboratory. *Irf3*^{-/-} and *Irf7*^{-/-} mice were provided by Dr. T. Taniguchi (University of Tokyo, Tokyo, Japan). *Myd88*^{-/-} mice were provided by Drs. K. Takeda and S. Akira (Osaka University, Osaka, Japan). All mice were maintained under specific pathogen-free conditions in the Animal Facility at Hokkaido University Graduate School of Medicine (Sapporo, Japan) and used when they were between 6 and 12 wk of age. This study was carried out in strict accordance with the recommendations in the National Institutes of Health *Guide for the Care and Use of Laboratory Animals*. The protocol was approved by the Committee on the Ethics of Animal Experiments in the Animal Safety Center, Hokkaido University. All mice were used according to the guidelines of the Institutional Animal Care and Use Committee of Hokkaido University, which approved this study as no.13-0024. All inoculation and experimental manipulation were performed with the animals under anesthesia that was induced and maintained with pentobarbital sodium, and all efforts were made to minimize suffering.

Virus and cell culture

Vero/CD150 cells were maintained in DMEM supplemented with 10% heat-inactivated FBS and antibiotics. IC323, corresponding to the IC-B strain of MV (27), was recovered from the plasmid p(+)MV323 encoding the antigenomic IC-B sequence (28). IC323-Luci (MV-luciferase), which expresses the reporter *Renilla* luciferase from the first gene position of the MV genome, was a kind gift from Dr. Y. Yanagi (Kyushu University, Fukuoka, Japan) (29). MV-luciferase was maintained in Vero/CD150 cells (30). Virus titer was determined as PFUs on Vero/CD150, and the multiplicity of infection (MOI) of each experiment was calculated based on this titer (27). Splenic CD19⁺, CD4⁺, CD8⁺ cells, and CD11c⁺ DCs were isolated using anti-CD19, anti-CD4, anti-CD8, and anti-CD11c MACS beads (Miltenyi Biotec). Splenic CD8 α ⁺ DCs, CD4⁺ DCs, and double negative (DN) DCs were isolated using CD8 α ⁺ or CD4⁺ DC isolation kits (Miltenyi Biotec) according to the manufacturer's instructions. For isolation of pDCs and conventional DCs (cDCs), spleens were treated with 400 IU Mandle U/ml collagenase D (Roche) at 37°C for 25 min in HBSS (Sigma-Aldrich). EDTA was added, and the cell suspension was incubated for an additional 5 min at 37°C. After removal of RBCs with ammonium chloride-potassium lysis buffer, CD11c⁺ DCs were isolated using CD11c MACS beads. MACS-sorted DCs were stained with anti-CD11b-FITC, anti-pDC Ag 1 (PDCA-1)-PE (eBioscience), and anti-CD11c-allophycocyanin (BioLegend) and sorted using a FACSaria II (BD). The purity of sorted cells was > 98%.

FACS analysis

For pDC staining, splenocytes were stained with anti-CD11c-allophycocyanin (BioLegend), anti-PDCA-1-PE (BioLegend), and anti-human CD150-FITC (eBiosciences). For CD4⁺ DCs, CD8⁺ DCs, and DN DCs staining, splenocytes were stained with anti-CD11c-allophycocyanin (BioLegend), anti-CD4-PerCP (BioLegend), anti-CD8-PE (BioLegend), and anti-human CD150-FITC. For B cell staining, splenocytes were stained with anti-B220-allophycocyanin (BioLegend), anti-CD19-PE (BioLegend), and anti-human CD150-FITC. For T cell staining, anti-CD3-allophycocyanin (BioLegend), anti-CD4-PerCP, anti-CD8-PE, and anti-human CD150-FITC were used. Fluorescence intensity of CD150 was measured by flow cytometry. For TLR7 intracellular staining in pDCs, DCs were stained with anti-

TLR7-FITC (IMGENEX), anti-CD11c-allophycocyanin, and anti-PDCA-1-PE using the BD Cytofix/Cytoperm Kit (BD Biosciences). For TLR7 intracellular staining in CD4⁺, CD8⁺, and DN DCs, DCs were stained with anti-TLR7-FITC (IMGENEX), anti-CD11c-allophycocyanin, anti-CD4-PerCP, and anti-CD8-PE, using the BD Cytofix/Cytoperm Kit (BD Biosciences). Stained cells were analyzed by flow cytometry.

Experimental infection and luciferase assay

Mice were infected i.p. with MV-luciferase at the indicated doses. For in vivo blockade of the type I IFNR, mice were i.p. injected with 2.5 mg MAR1-5A3, a mAb against IFNAR-1 (BioLegend), 1 d prior to infection. Tissues were collected from the mice at different time points, and the efficiency of infection was measured by luciferase assay. Cells (1×10^7) from various tissues were harvested in 100 μ l lysis buffer. The amount of protein in each lysate was determined by bicinchoninic acid assay. Luciferase assay was performed using a Dual-Luciferase Reporter Assay System (Promega), and luciferase activity was read using a Lumat LB 9507 (Berthold Technologies). To measure the efficiency of in vitro infection, cells (5×10^4 – 4×10^5) were harvested in 25 μ l lysis buffer for luciferase assay. For MyD88 inhibition assay, cells were pretreated with 50 μ M MyD88 inhibitory peptide (RQIKIWFQNRRMKWKK-RDVLPGTCVNS-NH2; InvivoGen) or the control peptide (RQIKIWFQNRRMKWKK-SLHGRGDPMEAFII-NH2; InvivoGen) for 6 h, and then cells were infected with MV. MyD88 inhibitory peptide contains a sequence from the MyD88 TIR homodimerization domain (RDVLPGT) preceded with a protein transduction sequence (RQIKIWFQNRRMKWKK) derived from antennapedia, which enables the peptide to translocate through the cell membrane. For intratracheal infection with MV, mice were anesthetized and injected with MV-luciferase (8×10^5 PFU/50 μ l in PBS) intratracheally. At 3 d after inoculation, mice were sacrificed and perfused with PBS containing 10 mM EDTA from the right ventricle. Lung lobes were isolated, and collagenase buffer [150 U/ml collagenase D (Roche), 10 μ g/ml DNase I (Takara), and 5% FCS in RPMI 1640 medium] was injected into the lobes, using a 27-gauge needle. The lobes were then shredded into small pieces and incubated at 37°C for 45 min. During the last 5 min, EDTA was added at 10 mM. Any remaining small pieces were dispersed by passage in and out through a 20-gauge needle, and the suspension was passed through nylon mesh to remove debris. A single-cell suspension was prepared after RBC lysis. A total of 2×10^6 cells were harvested in 100 μ l lysis buffer for luciferase assay.

ELISA

Culture supernatants of cells ($1-5 \times 10^5$) seeded on 96-well plates were collected and analyzed for cytokine levels, using ELISA. ELISA kits for mouse IFN- α and IFN- β were from PBL Biomedical Laboratories. Assays were performed according to the manufacturer's instructions.

RT-PCR and real-time PCR

Total RNA was prepared using TRIzol Reagent (Invitrogen) following the manufacturer's instructions. RT-PCR was carried out using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's instructions. Real-time PCR was performed using a StepOne Real-Time PCR System (Applied Biosystems). The following oligonucleotides were used for *β -actin*: 5'-TTTGCAGTCTTCGTTGC-3' and 5'-TCGTCATCCATGGCGAACT-3'; for *I β* : 5'-CCAGCTCCAAGAAAGG-ACGA-3' and 5'-CGCCCTGTAGGTGAGGTGTAG-3'; for *I α 4*: 5'-CTGCTGGCTGTGAGGACATACT-3' and 5'-AGGCACAGGGCTGTGT-TTCTT-3'; for *I β 1*: 5'-TGTGCTGAGATGAGCTGTGAG-3' and 5'-TTTCTGGCTCCACTTTCAGAG-3'; for *Cxcl10*: 5'-GTGTTGAGATCATTGCC-ACGA-3' and 5'-GCGTGGCTTCACTCCAGTTAA-3'; for *Tlr7*: 5'-GTAT-GCCGCCAAATCTAAAG-3' and 5'-GGCTGAGGTCCAAAATTTC-3'; and for *MV-P*: 5'-CTGCATCAGCAGTGTAAATC-3' and 5'-CTGGTGG-AACTTGGCAAGATC-3'. Levels of target mRNAs were normalized to *β -actin*, and fold-induction of transcripts was calculated using the ddCT method relative to unstimulated cells.

Statistical analyses

Statistical significance of differences between groups was determined by the Student *t* test using Microsoft Excel software. The *p* values < 0.05 were considered significant.

Results

CD150Tg/*Mavs*^{-/-} mice are not permissive to MV

To quantitate the efficiency of MV infection, we used a recombinant MV-luciferase that expresses the reporter *Renilla* luciferase from the insert of the MV genome (29). CD150 expression levels did

not differ among various spleen cells from CD150Tg, CD150Tg/*Irfnar*^{-/-}, CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-}, CD150Tg/*Ticam1*^{-/-} or CD150Tg/*Mavs*^{-/-} mice (Supplemental Fig. 1). Each knockout mouse strain was i.p. injected with 1×10^6 PFU of MV-luciferase. In accord with previous data (16, 22), luciferase activity in various tissues derived from MV-infected CD150Tg mice was very low 2 d after inoculation (Fig. 1A). In contrast, luciferase activity was predominantly increased in spleen and lymph nodes (LNs) derived

from MV-infected CD150Tg/*Irfnar*^{-/-} mice, compared with other tissues (Fig. 1A). *MV-P* mRNA expression was also increased in MV-infected CD150Tg/*Irfnar*^{-/-} spleen and LNs, similarly to luciferase activity (Fig. 1B). These results indicate that spleen and LNs are the major target tissues of i.p.-injected MV in CD150Tg/*Irfnar*^{-/-} mice, as shown in a previous report (24). Luciferase activity was increased in the lung of CD150Tg/*Irfnar*^{-/-}, but not CD150Tg/*Mavs*^{-/-}, mice after intratracheal injection of MV

FIGURE 1. CD150Tg/*Mavs*^{-/-} mice were resistant to in vivo MV infection. **(A)** CD150Tg, CD150Tg/*Irfnar*^{-/-}, CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-}, CD150Tg/*Mavs*^{-/-}, and CD150Tg/*Ticam1*^{-/-} mice were infected i.p. with 1×10^6 PFU MV-luciferase. After 2 d, cells were isolated from each organ and lysed with lysis buffer for luciferase assay. The amount of protein in each lysate was determined by bicinchoninic acid assay. Luciferase activity in each lysate was measured and normalized by the amount of protein. Data are shown as luciferase activity per 1 mg of protein and means \pm SD of three independent samples. **p* < 0.05. **(B)** CD150Tg/*Irfnar*^{-/-} mice were infected with MV (1×10^6 PFU). At 2 d after inoculation, total RNA was collected from the indicated tissues, and the expression level of *MV-P* mRNA in each tissue was determined by real-time PCR. *MV-P* mRNA expression is shown as expression relative to β -actin. Data are means \pm SD of three independent samples. **(C)** CD150Tg, CD150Tg/*Irfnar*^{-/-}, and CD150Tg/*Mavs*^{-/-} mice were intratracheally injected with MV-luciferase (8×10^5 PFU). At 3 d after inoculation, luciferase activity was measured in cells from lungs. Data are means \pm SD of two independent samples. **(D)** At the indicated days post infection (d.p.i.), luciferase activity in 1×10^7 splenocytes was measured. Three mice were analyzed for each genotype. Data are representative of two independent experiments. **p* < 0.05 versus CD150Tg. **(E)** CD150Tg, CD150Tg/*Irfnar*^{-/-}, and CD150Tg/*Mavs*^{-/-} mice were infected i.p. with 1×10^6 PFU MV-luciferase. At 2 d.p.i., CD19⁺, CD4⁺, CD8⁺, and CD11c⁺ cells were isolated from splenocytes, using anti-CD19, anti-CD4, anti-CD8, and anti-CD11c MACS beads. Luciferase activity in CD19⁺, CD4⁺, CD8⁺, and CD11c⁺ cells, as well as LNs, was measured and normalized by the total number of cells. Data are shown as the luciferase activity per 1×10^7 cells. Data are means \pm SD of three independent samples. **p* < 0.05. **(F)** CD150Tg, CD150Tg/*Irfnar*^{-/-}, CD150Tg/*Irf3*^{-/-}/*Irf7*^{-/-}, and CD150Tg/*Mavs*^{-/-} mice were infected i.p. with 1×10^6 PFU MV-luciferase. At 2 d.p.i., mRNA levels of *Irfn- β* , *Irf1*, and *Cxcl10* in spleens were determined by real time-PCR. Data are means \pm SD of three independent samples. **p* < 0.05.

